CM
KPTI icon

Caption Management’s Karyopharm Therapeutics KPTI Stock Holding History

Caption Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,332
Closed -$379K – 1159
2020
Q2 		$379K Buy
+1,332
New +$394K 0.01% 720
2019
Q3 		– Sell
-2,000
Closed -$271K – 806
2019
Q2 		$180K Buy
+2,000
New +$161K 0.01% 575

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Caption Management's KPTI Position: Q3 2020 in Review

Caption Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2020, closing a stake of 1,332 shares — an estimated $379K sold.

Caption Management first reported a position in KPTI in Q2 2019 and held it in 2 quarters. The position peaked at $379K in Q2 2020. 157 funds tracked by Wall St. Rank hold KPTI as of Q3 2020.

  • Caption Management reported no remaining Karyopharm Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Caption Management sold 1,332 Karyopharm Therapeutics shares in Q3 2020, an estimated $379K.
  • Caption Management first reported a position in Karyopharm Therapeutics in Q2 2019 and held it in 2 quarters.
  • Caption Management's Karyopharm Therapeutics position peaked at $379K in Q2 2020.
  • 157 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2020.

Based on Caption Management's 13F filing for Q3 2020, filed 16 Nov 2020.